OLINTATUG TESIRINE
UNII AJN3EUF4Z9

Substance Identification & Data

This profile provides standardized clinical and technical data for Olintatug Tesirine, uniquely identified by the FDA Unique Ingredient Identifier (UNII) AJN3EUF4Z9.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2851870-30-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

AJN3EUF4Z9

CAS Registry Number

2851870-30-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

OLINTATUG TESIRINE

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C181996

National Cancer Institute reference terminology for clinical and research data.

INN ID

13015

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Olintatug Tesirine

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Olintatug Tesirine. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Olintatug Tesirine

Common Names & Synonyms

H-gamma1 heavy chain humanized (1-445) [VH (Homo sapiens IGHV1-46*01 (80.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.9] (26-33.51-58.97-105)) (1-116) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (213) (117-214), hinge 1-15 (215-229), CH2 (230-339), CH3 D12 (355), L14 (357) (340-444), CHS K2>del (445)) (117-445)], (219-219')-disulfide with L-kappa light chain chimeric(1'-219') [V-KAPPA Musmus/Homsap (Mus musculus IGKV1-117*01 (89.0%) -IGKJ2*03 (90.9%) S120>Q (105)/Homo sapiens IGKV2-29*02 (89.0%) -IGKJ2*01 (100%), CDR-IMGT [11.3.9] (27'-37'.55'-57'.94'-102')) (1'-112') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (158'), V101 (196') (113'-219')]; dimer (225-225'':228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa; substituted at the sulfur atoms of 2-3 Lcysteinyl residues on an average among 219, 225, 228, 219', 219'', 225'', 228'' and 219''' with radical group (111aS,911S,911aS,16S,19S,523RS)-911-hydroxy-17,97-dimethoxy-12,92,16-trimethyl-15,95,10,15,18,21,49,522,525-nonaoxo-19-(propan-2-yl)-15,111a,911,911a-tetrahydro-11H,91H,95H-2,8,11,24,27,30,33,36,39,42,45-undecaoxa-14,17,20,48-tetraaza-1(8),9(8,10)-bis(pyrrolo[2,1-c][1,4]benzodiazepina)-52(1)-pyrrolidina-13(1,4)benzenadopentacontaphan-523-yl (tesirine)

Immunoglobulin G1 [de-C-terminal-lysine], anti-(human kidney-associated antigen 1) (human-Mus musculus monoclonal 3A4 γ1-chain), disulfide with human-Mus musculus monoclonal 3A4 κ-chain, dimer, reduced, thioether with N-[31-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1,29-dioxo-4,7,10,13,16,19,22,25-octaoxa-28-azahentriacont-1-yl]-L-valyl-N-[4-[[[[(11S,11aS)-8-[[5-[[(11aS)-5,11a-dihydro-7-methoxy-2-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy]pentyl]oxy]-11,11a-dihydro-11-hydroxy-7-methoxy-2-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-10(5H)-yl]carbonyl]oxy]methyl]phenyl]-L-alaninamide

immunoglobulin G1-kappa, anti-[Homo sapiens KAAG1 (kidney associated DCDC2 antisense RNA 1, kidney associated antigen 1, RU2AS, RU2 antisense gene protein)], humanized and chimeric monoclonal antibody, conjugated on an average of 2-3 cysteinyl residues to tesirine

olintatug tesirine [INN]

External Clinical & Regulatory Resources

Previous UNIIAJM9X4M2MZ

Next UNIIAJN4H59VT3